Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ambrogio GAGLIANO"'
Autor:
Andrea De Giglio, Federico Zacchini, Giulia Venturi, Alessandro Di Federico, Claudia Parisi, Filippo Gustavo Dall’Olio, Ilaria Ricciotti, Valentina Favorito, Ambrogio Gagliano, Dario De Biase, Thais Maloberti, Annalisa Altimari, Elisa Gruppioni, Giovanni Tallini, Barbara Melotti, Francesca Sperandi, Francesco Gelsomino, Lorenzo Montanaro, Andrea Ardizzoni
Publikováno v:
The Journal of Liquid Biopsy, Vol 6, Iss , Pp 100161- (2024)
Background: The frontline management of non-oncogene addicted non-small cell lung cancer (NSCLC) involves immune-checkpoint inhibitors (ICI) alone or combined with chemotherapy (CT-ICI). The dynamic landscape of KRAS-positive NSCLC presents a spectru
Externí odkaz:
https://doaj.org/article/2c56aaec253547179fef60b4afe1ddfb
Autor:
Ambrogio Gagliano, Angela Prestifilippo, Ornella Cantale, Gianluca Ferini, Giacomo Fisichella, Paolo Fontana, Dorotea Sciacca, Dario Giuffrida
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Targeting cell cycle has become the gold standard for metastatic breast cancer (MBC), being cyclin-dependent kinase inhibitors (CDKIs) cornerstones of its treatment, alongside radiotherapy (RT). To date, no definite evidence regarding safety and effi
Externí odkaz:
https://doaj.org/article/2009b59c00f04daf976b87057fe6d230
Autor:
Francesca COMITO, Ambrogio GAGLIANO, Francesca SPERANDI, Emi DIKA, Francesco SAVOIA, Barbara MELOTTI
Publikováno v:
Italian Journal of Dermatology and Venereology. 158
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::847d5b017cf1166c57b42efc731c78f3
https://doi.org/10.23736/s2784-8671.23.07281-x
https://doi.org/10.23736/s2784-8671.23.07281-x
Autor:
Paolo Fontana, Angela Prestifilippo, Giacomo Fisichella, Dorotea Sciacca, Gianluca Ferini, Ambrogio Gagliano, Ornella Cantale, Dario Giuffrida
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Targeting cell cycle has become the gold standard for metastatic breast cancer (MBC), being cyclin-dependent kinase inhibitors (CDKIs) cornerstones of its treatment, alongside radiotherapy (RT). To date, no definite evidence regarding safety and effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f39487e7c8b56aefd437e7c5a6a6444d
https://pubmed.ncbi.nlm.nih.gov/34221963
https://pubmed.ncbi.nlm.nih.gov/34221963